Retlirafusp alfa is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Squamous Non-Small Cell Lung Cancer have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Retlirafusp alfa’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Retlirafusp alfa overview

SHR-1701 is under development for the treatment of advanced unresectable or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma, metastatic pancreatic cancer,  recurrent or metastatic cervical cancer, advanced melanoma, relapsed and refractory solid tumors including metastatic colorectal cancer (mCRC), squamous cell or non-squamous non-small cell lung cancer, recurrent or metastatic squamous cell carcinoma of the head and neck, advanced pancreatic cancer, hepatocellular carcinoma, rectal cancer, biliary tract cancer and recurrent or metastatic nasopharyngeal carcinoma. The therapeutic candidate is administered as intravenous drip. It is a bifunctional fusion protein composed of a mAb against programmed death ligand 1 (PD L1) fused with the extracellular domain of TGFbeta receptor II.

It was also under development for the treatment of small cell lung cancer.

Jiangsu Hengrui Medicine overview

Jiangsu Hengrui Medicine (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US, and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland, and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China.

For a complete picture of Retlirafusp alfa’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.